vs

Side-by-side financial comparison of Lineage Cell Therapeutics, Inc. (LCTX) and Lake Shore Bancorp, Inc. (LSBK). Click either name above to swap in a different company.

Lake Shore Bancorp, Inc. is the larger business by last-quarter revenue ($7.4M vs $6.6M, roughly 1.1× Lineage Cell Therapeutics, Inc.). Lake Shore Bancorp, Inc. runs the higher net margin — 31.8% vs 12.9%, a 18.9% gap on every dollar of revenue. Lake Shore Bancorp, Inc. produced more free cash flow last quarter ($3.3M vs $-5.3M).

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

Lake Shore Bancorp, Inc. (Maryland) is a U.S. regional bank holding company that operates via its banking subsidiary, offering retail and commercial banking services including deposits, loans, mortgages and wealth management, primarily serving individuals and SMEs across local communities in Maryland.

LCTX vs LSBK — Head-to-Head

Bigger by revenue
LSBK
LSBK
1.1× larger
LSBK
$7.4M
$6.6M
LCTX
Higher net margin
LSBK
LSBK
18.9% more per $
LSBK
31.8%
12.9%
LCTX
More free cash flow
LSBK
LSBK
$8.6M more FCF
LSBK
$3.3M
$-5.3M
LCTX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
LCTX
LCTX
LSBK
LSBK
Revenue
$6.6M
$7.4M
Net Profit
$851.0K
$2.4M
Gross Margin
Operating Margin
-99.1%
38.4%
Net Margin
12.9%
31.8%
Revenue YoY
130.4%
Net Profit YoY
126.0%
EPS (diluted)
$0.00
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LCTX
LCTX
LSBK
LSBK
Q4 25
$6.6M
Q3 25
$3.7M
$7.4M
Q2 25
$2.8M
$6.9M
Q1 25
$1.5M
Q4 24
$2.9M
Q3 24
$3.8M
Q2 24
$1.4M
Q1 24
$1.4M
Net Profit
LCTX
LCTX
LSBK
LSBK
Q4 25
$851.0K
Q3 25
$-29.8M
$2.4M
Q2 25
$-30.5M
$1.9M
Q1 25
$-4.1M
Q4 24
$-3.3M
Q3 24
$-3.0M
Q2 24
$-5.8M
Q1 24
$-6.5M
Gross Margin
LCTX
LCTX
LSBK
LSBK
Q4 25
Q3 25
Q2 25
Q1 25
97.6%
Q4 24
94.6%
Q3 24
99.0%
Q2 24
96.9%
Q1 24
93.2%
Operating Margin
LCTX
LCTX
LSBK
LSBK
Q4 25
-99.1%
Q3 25
-102.9%
38.4%
Q2 25
-715.4%
33.2%
Q1 25
-433.1%
Q4 24
-178.2%
Q3 24
-101.6%
Q2 24
-416.7%
Q1 24
-461.3%
Net Margin
LCTX
LCTX
LSBK
LSBK
Q4 25
12.9%
Q3 25
-809.0%
31.8%
Q2 25
-1101.8%
27.7%
Q1 25
-275.6%
Q4 24
-114.1%
Q3 24
-80.3%
Q2 24
-409.1%
Q1 24
-453.0%
EPS (diluted)
LCTX
LCTX
LSBK
LSBK
Q4 25
$0.00
Q3 25
$-0.13
$0.32
Q2 25
$-0.13
$0.34
Q1 25
$-0.02
Q4 24
$0.00
Q3 24
$-0.02
Q2 24
$-0.03
Q1 24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LCTX
LCTX
LSBK
LSBK
Cash + ST InvestmentsLiquidity on hand
$55.8M
$83.6M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$44.5M
$139.3M
Total Assets
$112.6M
$742.8M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LCTX
LCTX
LSBK
LSBK
Q4 25
$55.8M
Q3 25
$40.5M
$83.6M
Q2 25
$42.3M
$75.4M
Q1 25
$47.9M
Q4 24
$47.8M
Q3 24
$32.7M
Q2 24
$38.5M
Q1 24
$43.6M
Total Debt
LCTX
LCTX
LSBK
LSBK
Q4 25
Q3 25
$2.0M
Q2 25
$2.0M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
LCTX
LCTX
LSBK
LSBK
Q4 25
$44.5M
Q3 25
$22.0M
$139.3M
Q2 25
$48.4M
$92.9M
Q1 25
$79.0M
Q4 24
$78.4M
Q3 24
$66.2M
Q2 24
$68.3M
Q1 24
$72.4M
Total Assets
LCTX
LCTX
LSBK
LSBK
Q4 25
$112.6M
Q3 25
$89.6M
$742.8M
Q2 25
$90.8M
$734.8M
Q1 25
$111.8M
Q4 24
$113.2M
Q3 24
$96.6M
Q2 24
$102.8M
Q1 24
$108.5M
Debt / Equity
LCTX
LCTX
LSBK
LSBK
Q4 25
Q3 25
0.01×
Q2 25
0.02×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LCTX
LCTX
LSBK
LSBK
Operating Cash FlowLast quarter
$-4.9M
$3.3M
Free Cash FlowOCF − Capex
$-5.3M
$3.3M
FCF MarginFCF / Revenue
-79.9%
44.4%
Capex IntensityCapex / Revenue
6.0%
0.6%
Cash ConversionOCF / Net Profit
-5.73×
1.42×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LCTX
LCTX
LSBK
LSBK
Q4 25
$-4.9M
Q3 25
$-3.6M
$3.3M
Q2 25
$-5.5M
$2.5M
Q1 25
$-4.9M
Q4 24
$-6.3M
Q3 24
$-5.8M
Q2 24
$-5.2M
Q1 24
$-5.8M
Free Cash Flow
LCTX
LCTX
LSBK
LSBK
Q4 25
$-5.3M
Q3 25
$-3.6M
$3.3M
Q2 25
$-5.6M
$2.0M
Q1 25
$-5.0M
Q4 24
$-6.7M
Q3 24
$-5.9M
Q2 24
$-5.2M
Q1 24
$-5.8M
FCF Margin
LCTX
LCTX
LSBK
LSBK
Q4 25
-79.9%
Q3 25
-98.6%
44.4%
Q2 25
-200.8%
28.5%
Q1 25
-331.8%
Q4 24
-234.0%
Q3 24
-156.1%
Q2 24
-371.2%
Q1 24
-403.1%
Capex Intensity
LCTX
LCTX
LSBK
LSBK
Q4 25
6.0%
Q3 25
0.3%
0.6%
Q2 25
0.5%
7.7%
Q1 25
6.5%
Q4 24
12.7%
Q3 24
3.0%
Q2 24
3.6%
Q1 24
2.6%
Cash Conversion
LCTX
LCTX
LSBK
LSBK
Q4 25
-5.73×
Q3 25
1.42×
Q2 25
1.31×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

LSBK
LSBK

Segment breakdown not available.

Related Comparisons